Months after a sexual harassment scandal, OrbiMed’s banking another billion

Months after being rocked by sexual harassment allegations, biotech’s largest investment fund is in process of raising $1 billion from investors, its largest offering to date, while the founder who was at the center of the controversy remains a partner at the firm.

Legendary biotech financier Sam Isaly said late last year that he would retire following publication of a STAT investigation in which six former OrbiMed employees said he regularly sexually harassed the firm’s female employees, particularly executive assistants.

But recent filings with the Securities. The Wall Street firm and Isaly are in the process of negotiating his departure, but it’s unclear how long those talks might take.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min read
Opinion: CBO Estimate On Pelosi Drug Bill Misses Its Long-term Impact On Health
The CBO estimate on Speaker Nancy Pelosi's drug pricing bill misses its long-term impact on health.
STAT5 min readScience
Opinion: Using CRISPR To Edit Eggs, Sperm, Or Embryos Does Not Save Lives
The real value of using CRISPR on eggs, sperm, or embryos accrues not to the individual who is created but to the people who choose to use it to create…
STAT4 min readSociety
An ‘Unprecedented’ Analysis Underlines Profound Failure To Study African Genomes
It has become the geneticist’s version of, “What, me not inclusive? But I have a black friend!” In the case of modern studies of DNA, researchers called to task for studying mainly European populations often defend themselves by pointing out that the